VivoSeq
Oncology

Non-Small Cell Lung Carcinoma

74

Pipeline Programs↗

16

Active Trials↗

38

Companies Involved↗

Non-Small Cell Lung Carcinoma is a moderately active landscape with 74 programs across 38 companies. The most active players are Boehringer Ingelheim, Synta Pharmaceuticals Corp., Bayer. 7 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

30/100

Mech. Concentration

8/100

Completion Rate

70/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1S

Synta Pharmaceuticals Corp.

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 2S

Syndax Pharmaceuticals

1 program

Phase 2B

Betta Pharmaceuticals Co., Ltd.

1 program

Phase 2GSK logo

GSK

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

49 of 69 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody1522%Antibody–drug conjugate23%Protein / enzyme23%Gene therapy11%

Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 91% of 81 pipeline programs.

Analysis

Trial Status

43

clinical trials

Completed16 · 37%
Recruiting8 · 19%
Terminated6 · 14%
Unknown status4 · 9%
Active, not recruiting4 · 9%
Not yet recruiting3 · 7%
Other2 · 5%

Clinical Trials

Trial Activity

43 trials

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
Recruiting·—·Phase 2·NCT06014827·32 enrolled
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT04853342·318 enrolled
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Recruiting·JJuan LI, MD·Phase 2·NCT06192849·20 enrolled
KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Recruiting·Novartis logoNovartis·Preclinical·NCT07468071·40 enrolled
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT07221474·180 enrolled
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Recruiting·Pfizer logoPfizer·Preclinical·NCT07227298·162 enrolled
A Phase 2 Study to Investigate Ubamatamab With and Without REGN7075 in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recruiting·Regeneron logoRegeneron·Phase 2·NCT07154290·300 enrolled
A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment
Recruiting·CCandel Therapeutics, Inc.·Phase 3·NCT07660094·500 enrolled
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Active, not recruiting·—·Phase 2·NCT03808558·18 enrolled
Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas
Active, not recruiting·UUniversity of Sao Paulo·Phase 2/3·NCT06872541·100 enrolled
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT05526755·188 enrolled
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT02511106·682 enrolled
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Not yet recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT07420439·108 enrolled
A Prospective Single-Arm Clinical Study of Recakimab for Lorlatinib-Induced Hypercholesterolemia / Mixed Hyperlipidemia
Not yet recruiting·HHunan Cancer Hospital·Approved·NCT07674368·29 enrolled
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive Non-small Cell Lung Cancer(NSCLC): An Exploratory Analysis
Not yet recruiting·—·Approved·NCT07671560·80 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)